Pharmacological interventions on early functional gastrointestinal disorders

Area of Science:

• Pediatrics
• Gastroenterology
• Evidence-Based Medicine

Background:

• Functional gastrointestinal disorders (FGIDs) are common in infants and toddlers, presenting with chronic or recurrent symptoms without identifiable structural or biochemical causes.
• These multifactorial conditions involve altered motility, visceral hypersensitivity, and brain-gut interactions, often leading to interventions despite limited evidence.
• Current literature lacks robust data on the efficacy and appropriateness of drug treatments for early-onset FGIDs.

Purpose of the Study:

• To critically review existing literature on the effects and clinical appropriateness of drug treatments for functional gastrointestinal disorders in infants and toddlers.
• To identify evidence-based recommendations for pharmacological interventions in early FGIDs.

Main Methods:

• Systematic literature search of Medline and GIMBE databases using Critically Appraised Topics (CATs) methodology.
• Inclusion of systematic reviews, clinical studies, evidence-based guidelines, and randomized controlled trials (RCTs) on pharmacologic therapies in children with early FGIDs.
• Data extraction focused on participants, interventions, and outcomes related to pharmacological treatments.

Main Results:

• No evidence-based guidelines or systematic reviews were found for functional regurgitation, infant colic, or functional diarrhea.
• Alginate may be considered for regurgitation with distress after non-pharmacological approaches fail.
• Lactulose is recommended for constipation in infants under 6 months; Polyethylene glycol (PEG) is first-line for older infants for disimpaction and maintenance. No evidence supports laxatives for dyschezia.
• Retrospective studies suggest potential efficacy of cyproheptadine, propranolol, and pizotifen for cyclic vomiting syndrome, though no RCTs exist.

Conclusions:

• Pharmacological intervention, specifically Polyethylene glycol (PEG), is supported for childhood constipation disimpaction and maintenance therapy.
• A significant lack of well-designed, high-quality RCTs exists for other early functional gastrointestinal disorders, indicating insufficient evidence for pharmacological treatment.
• Further research is needed to establish evidence-based pharmacological strategies for most infant FGIDs.